Is Cassava Sciences Back in the Game?

Is Cassava Sciences Back in the Game?

Source: 
Motley Fool
snippet: 
  • Consider the Alzheimer's candidate's latest data in context, not just at face value. 
  • Without a control group, its reported efficacy could be a fluke.
  • Investors should look to Biogen's controversial FDA approval for clues.